Shigeyuki Matsumoto
Overview
Explore the profile of Shigeyuki Matsumoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
362
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cozac R, Hasic H, Choong J, Richard V, Beheshti L, Froehlich C, et al.
J Cheminform
. 2025 Feb;
17(1):22.
PMID: 40001146
Machine learning is quickly becoming integral to drug discovery pipelines, particularly quantitative structure-activity relationship (QSAR) and absorption, distribution, metabolism, and excretion (ADME) tasks. Graph Convolutional Network (GCN) models have proven...
2.
Park Y, Matsumoto S, Ogata K, Ma B, Kanada R, Isaka Y, et al.
J Biol Chem
. 2024 Dec;
301(2):108136.
PMID: 39730062
Alpha-1-antitrypsin (AAT), a circulating serine protease inhibitor, is an acute inflammatory response protein with anti-inflammatory functions. The C-terminal peptides of AAT are found in various tissues and have been proposed...
3.
Toda Y, Fujita H, Mino K, Koyama T, Matsuoka S, Kaizuka T, et al.
Cell Death Dis
. 2024 Nov;
15(11):813.
PMID: 39528476
The linear ubiquitin chain assembly complex (LUBAC) plays crucial roles in NF-κB signaling and protection against cell death by generating linear ubiquitin chains. Its accessory subunits, HOIL-1L and SHARPIN, regulate...
4.
Araki M, Ekimoto T, Takemura K, Matsumoto S, Tamura Y, Kokubo H, et al.
J Am Chem Soc
. 2024 Oct;
146(42):28685-28695.
PMID: 39394997
The sensitivity to protein inhibitors is altered by modifications or protein mutations, as represented by drug resistance. The mode of stable drug binding to the protein pocket has been experimentally...
5.
Matsumoto S, Ishida S, Terayama K, Okuno Y
Biophys Physicobiol
. 2024 Mar;
20(2):e200022.
PMID: 38496243
Protein functions associated with biological activity are precisely regulated by both tertiary structure and dynamic behavior. Thus, elucidating the high-resolution structures and quantitative information on in-solution dynamics is essential for...
6.
Igarashi Y, Kojima R, Matsumoto S, Iwata H, Okuno Y, Yamada H
J Toxicol Sci
. 2024 Mar;
49(3):117-126.
PMID: 38432954
Mitochondrial toxicity has been implicated in the development of various toxicities, including hepatotoxicity. Therefore, mitochondrial toxicity has become a major screening factor in the early discovery phase of drug development....
7.
Suzuki M, Uchibori K, Oh-Hara T, Nomura Y, Suzuki R, Takemoto A, et al.
NPJ Precis Oncol
. 2024 Feb;
8(1):46.
PMID: 38396251
Brigatinib-based therapy was effective against osimertinib-resistant EGFR C797S mutants and is undergoing clinical studies. However, tumor relapse suggests additional resistance mutations might emerge. Here, we first demonstrated the binding mode...
8.
Iwata H, Nakai T, Koyama T, Matsumoto S, Kojima R, Okuno Y
J Chem Inf Model
. 2023 Nov;
63(23):7392-7400.
PMID: 37993764
Molecular generation is crucial for advancing drug discovery, materials science, and chemical exploration. It expedites the search for new drug candidates, facilitates tailored material creation, and enhances our understanding of...
9.
Koyama T, Matsumoto S, Iwata H, Kojima R, Okuno Y
J Chem Inf Model
. 2023 Jul;
63(15):4552-4559.
PMID: 37460105
Identifying compound-protein interactions (CPIs) is crucial for drug discovery. Since experimentally validating CPIs is often time-consuming and costly, computational approaches are expected to facilitate the process. Rapid growths of available...
10.
Tabata J, Nakaoku T, Araki M, Yoshino R, Kohsaka S, Otsuka A, et al.
Cancer Res
. 2022 Sep;
82(20):3751-3762.
PMID: 36166639
Significance: Comprehensive proteogenomic and in silico analyses of a vast number of VUSs identify a novel set of oncogenic and druggable mutations in the well-characterized RET oncogene.